Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk

Cancer Prevention Research

Volumn 8, Issue 6, 2015, Pages 528-534

  Nichols, Hazel B ^a   Baird, Donna D ^b   Stanczyk, Frank Z ^c   Steiner, Anne Z ^d   Troester, Melissa A ^a   Whitworth, Kristina W ^e   Sandler, Dale P ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MUELLERIAN INHIBITING FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; HUMAN; INVESTIGATIVE PROCEDURES; LIFESTYLE; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; BLOOD; BREAST; BREAST NEOPLASMS; CANCER STAGING; COMPARATIVE STUDY; FEMALE; FOLLOW UP; MIDDLE AGED; PROGNOSIS; RISK FACTOR; STATISTICAL MODEL; UNITED STATES;

ADULT; ANTI-MULLERIAN HORMONE; BIOMARKERS, TUMOR; BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM STAGING; PREMENOPAUSE; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 84941771008     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0377     Document Type: Article

References (34)

1. Visser JA, Schipper I, Laven JS, Themmen AP. Anti-Mullerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol 2012;8:331-41.
2. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, etal. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014;20:804.
3. Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone asa predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab 2012;97:1673-80.
4. Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, et al. Anti-mullerian hormoneand inhibin Bin the definitionofovarian aging and the menopause transition. J Clin Endocrinol Metab 2008;93:3478-83.
5. Lie Fong S, Visser JA, Welt CK, de Rijke YB, Eijkemans MJ, Broekmans FJ, et al. Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab 2012;97:4650-5.
6. Gupta V, Carey JL, Kawakubo H, Muzikansky A, Green JE, Donahoe PK, et al. Mullerian inhibiting substance suppresses tumor growth in the C3 (1) T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci U S A 2005;102:3219-24.
7. Hoshiya Y, Gupta V, Segev DL, Hoshiya M, Carey JL, Sasur LM, et al. Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells. Mol Cell Endocrinol 2003;211:43-9.
8. Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, et al. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway. J Biol Chem 2000;275:28371-9.
9. Segev DL, Hoshiya Y, Stephen AE, Hoshiya M, Tran TT, MacLaughlin DT, et al. Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo. J Biol Chem 2001;276:26799-806.
10. Perou CM, Sorlie T, Eisen MB, vande Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
11. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
12. Dorgan JF, Stanczyk FZ, Egleston BL, Kahle LL, Shaw CM, Spittle CS, et al. Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk. J Natl Cancer Inst 2009;101:1501-9.
13. Breast cancer facts & figures 2013-14. Atlanta: American Cancer Society.
14. McCoy AC, Kliethermes B, Zhang K, Qin W, Sticca R, Bouton M, et al. Serum Mullerian inhibiting substance levels are lower in premenopausal women with breast precancer and cancer. BMC Res Notes 2011;4:152.
15. Su HI, Flatt SW, Natarajan L, De Michele A, Steiner AZ. Impact of breast cancer on anti-mullerian hormone levels in young women. Breast Cancer Res Treat 2013;137:571-7.
16. Goebelsmann U, Arce JJ, Thorneycroft IH, Mishell DR Jr. Serum testosterone concentrations in women throughout the menstrual cycle and following HCG administration. Am J Obstet Gynecol 1974;119:445-52.
17. Breslow NE, Day NE. Statistical methods in cancer research, Volume I - The analysis of case-control studies. Lyon, IARC. 2000.
18. Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. Hoboken, NJ: Wiley & Sons; 2013.
19. MacLaughlin DT, Donahoe PK. Mullerian inhibiting substance/anti-Mullerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol 2010;6:391-405.
20. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39.
21. Sweeney C, Bernard PS, Factor RE, Kwan ML, Habel LA, Quesenberry CP Jr, et al. Intrinsic subtypes from PAM50 gene expression assayina populationbased breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev 2014;23:714-24.
22. Tehrani FR, Solaymani-Dodaran M, Azizi F. A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause. Menopause 2009;16:797-802.
23. Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011;96:2532-9.
24. Kevenaar ME, Themmen AP, Rivadeneira F, Uitterlinden AG, Laven JS, van Schoor NM, et al. A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum Reprod 2007;22:2382-8.
25. Kvale G, Heuch I. Menstrual factors and breast cancer risk. Cancer 1988;62:1625-31.
26. Phipps AI, Ichikawa L, Bowles EJ, Carney PA, Kerlikowske K, Miglioretti DL, et al. Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 2010;67:60-6.
27. Chai J, Howie AF, Cameron DA, Anderson RA. A highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 2014;50:2367-74.
28. Su HI, Sammel MD, Homer MV, Bui K, Haunschild C, Stanczyk FZ. Comparability of antimullerian hormone levels among commercially available immunoassays. Fertil Steril 2014;101:1766-72 e1.
29. Robertson DM, Hale GE, Fraser IS, Hughes CL, Burger HG. Changes in serum antimullerian hormone levels across the ovulatory menstrual cycle in late reproductive age. Menopause 2011;18:521-4.
30. Hankinson SE, Eliassen AH. Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer 2010;1:2-10.
31. Pinola P, Morin-Papunen LC, Bloigu A, Puukka K, Ruokonen A, Jarvelin MR, et al. Anti-Mullerian hormone: correlation with testosterone and oligo-oramenorrhoeainfemale adolescenceinapopulation-based cohort study. Hum Reprod 2014;29:2317-25.
32. Woo HY, Kim KH, Rhee EJ, Park H, Lee MK. Differences of the association of anti-Mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J 2012;59:781-90.
33. Endogenous Hormones and Breast Cancer Collaborative Group. Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarte A, et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol. 2013;14:1009-19.
34. Hankinson SE. Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 2005;24:3-15.